HLA-A*02:01-POSITIVE
Clinical trials for HLA-A*02:01-POSITIVE explained in plain language.
Never miss a new study
Get alerted when new HLA-A*02:01-POSITIVE trials appear
Sign up with your email to follow new studies for HLA-A*02:01-POSITIVE, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New immune drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage trial tests a new drug called IMC-P115C in people with advanced cancers that have a specific protein (PRAME) and a certain immune type (HLA-A*02:01). The drug is designed to help the immune system find and attack cancer cells. The study will check safety and whet…
Matched conditions: HLA-A*02:01-POSITIVE
Phase: PHASE1 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New bispecific drug targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis study tests a new drug called IMC-R117C, alone or with other cancer drugs, in people with advanced colorectal, esophageal, stomach, or ovarian cancers that have a specific genetic marker (HLA-A*02:01) and produce a protein called PIWIL1. The trial aims to find safe doses and…
Matched conditions: HLA-A*02:01-POSITIVE
Phase: PHASE1, PHASE2 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC